Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Warrants "A"

<< Previous

Bullboard Posts

Next >>

Post by hotinfoon Aug 04, 2021 2:34pm

180 Views

Post# 33649187

Warrants "A"

now this stock is speculative to a certain point BUT
someone actually bought A warrants that expire 8/8/21 !!! WOW

that's not called speculation , .... that's called ............ (there are guidelines here to respect LOL)

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market